Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Alphamab Oncology ( (HK:9966) ).
Alphamab Oncology has received a three-year waiver from the Hong Kong Stock Exchange, allowing the appointment of Ms. Jiang Rui as joint company secretary despite her not yet meeting the usual academic or professional criteria required under the Listing Rules. During this waiver period, Ms. Jiang will be assisted by qualified company secretary Ms. Chan Lok Yee, and the waiver may be revoked in the event of material breaches, underscoring the exchange’s conditional support for the company’s governance arrangements.
The company must demonstrate before the waiver expires that Ms. Jiang has gained sufficient relevant experience to independently fulfill the role without further regulatory exemption, a process that could influence the firm’s longer-term compliance posture and administrative stability. The board has confirmed Ms. Jiang’s appointment effective April 8, 2026, signaling continuity in corporate secretarial functions while the company navigates regulatory requirements and strengthens its internal governance capacity.
The most recent analyst rating on (HK:9966) stock is a Buy with a HK$9.60 price target. To see the full list of analyst forecasts on Alphamab Oncology stock, see the HK:9966 Stock Forecast page.
More about Alphamab Oncology
Alphamab Oncology is a Hong Kong-listed biopharmaceutical company focused on oncology, developing and commercializing innovative cancer therapies. The company operates in the healthcare and life sciences sector, with its shares traded under stock code 9966 on the Stock Exchange of Hong Kong.
Average Trading Volume: 1,605,344
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$11.11B
See more data about 9966 stock on TipRanks’ Stock Analysis page.